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In many countries, including Korea, Mycobacterium avium complex (MAC),
which includes Mycobacterium avium and Mycobacterium intracellulare, is the
most common etiology of lung disease caused by nontuberculous mycobacteria
(NTM).
1,2 Currently, the accepted standard therapy for patients with MAC lung
disease involves the use of a macrolide-based multidrug regimen that consists of a
macrolide (clarithromycin or azithromycin), a rifamycin (rifampicin or rifabutin),
and ethambutol with or without initial use of streptomycin or amikacin.
3,4 How-
ever, available data on macrolide-based therapy demonstrate that successful
eradication of MAC pulmonary infection is achieved in only 60% of human
immunodeficiency virus (HIV)-negative patients.
5
In Korea, the Korean Academy of Tuberculosis and Respiratory Diseases
recommends a combination antibiotic therapy that includes daily clarithromycin,
rifampicin, and ethambutol with or without initial use of streptomycin.
6 At our
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Purpose: The optimal treatment regimen for Mycobacterium avium complex
(MAC) lung disease has not yet been fully established. We evaluated the efficacy
of standardized combination antibiotic therapy and the factors that might affect
unfavorable microbiologic responses in patients with MAC pulmonary disease.
Materials and Methods: This retrospective study reviewed data from 96 patients
(56 females; median age 59 years) treated with newly diagnosed MAC lung
disease between January 2003 and December 2006. Results: All patients received
standardized combination antibiotic therapy, consisting of clarithromycin, rifam-
picin, and ethambutol. Streptomycin was additionally given in 72 patients (75%)
for a median duration of 4.5 months. The overall favorable microbiologic response
rate was 79% (76/96); 20 patients (21%) had unfavorable microbiologic respon-
ses, including failure to sputum conversion (n = 13), relapse (n = 3), and MAC-
related death (n = 4). A positive sputum acid-fast bacillus smear at the start of
treatment was an independent predictor of an unfavorable microbiologic response.
Conclusion: Standardized combination antibiotic therapy consisting of clarith-
romycin, rifampicin, and ethambutol with or without initial use of streptomycin is
effective in treating patients with newly diagnosed MAC lung disease.  
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INTRODUCTIONinstitution, we typically prescribe this triple-drug regimen
for the treatment of MAC lung disease. Furthermore,
streptomycin has actively been used in patients with radio-
graphically extensive or cavitary disease, especially when
accompanied by positive sputum smears.
7 In the present
study, we evaluated the efficacy of this standardized com-
bination antibiotic therapy and the factors that might affect
unfavorable microbiologic responses in patients with MAC
pulmonary disease.
Study population
We retrospectively reviewed the medical records of all pat-
ients treated for MAC lung disease at the Samsung Medical
Center (a 1,250-bed referral hospital in Seoul, South Korea)
between January 2003 and December 2006. During this
period, 248 patients were newly diagnosed with MAC
lung disease. All patients met the diagnostic criteria for
NTM lung disease according to standards set by the
American Thoracic Society in 1997.
3 No patients had pre-
viously been treated for MAC lung disease before visiting
our hospital. 
NTM lung disease may progress very slowly. Further-
more, some patients do not require treatment, whereas
others require combination antibiotic therapy, including
parenteral agents. After discussing this information with
patients, we implemented an observation period of at least
6-12 months with no antibiotic treatment. When the disease
was clearly recognized as being progressive, patients
received a standardized combination antibiotic therapy
following hospitalization. In patients with substantial sym-
ptoms and/or advanced or progressive radiographic abnor-
malities, antibiotic therapy was initiated immediately.
8
Out of 248 patients with MAC lung disease, 121 patients
(49%) did not receive antibiotic therapy, and 127 patients
(51%) received combination antibiotic therapy by the end
of September 2008. Of these 127 patients who initiated
combination antibiotic therapy, 31 patients were excluded
because they had received antibiotic therapy for less than
12 months at the time of analysis. These included MAC-
unrelated death (n = 3), default (n = 12), transfer out (n = 5),
and still on treatment (n = 11). However, 3 patients who
died of MAC lung disease were included in the study, even
though they were on less than 12 months of antibiotic
therapy. Therefore, a total of 96 patients were included in
the study. Permission was obtained from the institutional
review board of Samsung Medical Center to review and
publish information from the patients’ records. Informed
consent was waived because of the retrospective nature of
the study.
Microbiological examination
Smears for microscopic examination were prepared from
concentrated specimens and stained with auramine-rhoda-
mine. Smears were then examined under a fluorescent
microscopy. Samples positive for acid-fast bacilli (AFB)
were reviewed after staining by using the carbol fuchsin
staining method. The results of smear microscopy were
reported semiquantitatively. A positive smear was defined
as one with > 1 AFB per 100 high-power fields.
9
Respiratory specimens were decontaminated using N-
acetyl-L-cysteine/2% NaOH, and processed specimens
were plated on 3% Ogawa medium (Shinyang, Seoul,
Korea). Inoculated tubes were incubated at 37˚C and then
inspected weekly for 8 weeks. All AFB isolates were
assessed to distinguish between M. tuberculosis and NTM
with a commercially available polymerase chain reaction-
based assay system (MTB-ID, M&D Inc., Wonju, Korea).
NTM species were identified using a polymerase chain
reaction and restriction fragment length polymorphism
methods based on the rpoB gene, as described previously
(Myco-ID, M&D Inc., Wonju, Korea).
2
Clarithromycin susceptibility was tested at the Korean
Institute of Tuberculosis. Minimal inhibitory concentra-
tions of clarithromycin were determined using the broth
microdilution method and interpreted according to the
Clinical and Laboratory Standards Institute guidelines.
10
Isolates with minimal inhibitory concentrations of 32
µg/mL or greater were considered resistant.
10 Methods for
determining broth microdilution minimal inhibitory con-
centration were not established in Korea during the early
study period, therefore, isolates recovered from only 68 of
96 patients (71%) could be tested for susceptibility to
clarithromycin.
Radiological examination
Chest radiography and high-resolution computed tomo-
graphy (HRCT) findings were classified as showing either
upper lobe cavitary disease or nodular bronchiectatic
disease.
11-13 A combination of cavities, consolidation, and
pleural thickening in the upper lobes was considered upper
lobe cavitary disease, regardless of whether reticulonodular
opacities were present. Bilateral bronchiectasis and no-
dular changes that were observed predominantly in the
middle and lower lung zones without visible cavities in the
upper lobes were considered nodular bronchiectatic
disease. When the disease did not belong to either the
upper lobe cavitary or the nodular bronchiectatic forms, it
was deemed unclassifiable.
11-13 Initial and available follow-
up HRCT scans were reviewed by two of the authors (Sim
YS and Park HY). Differences in observed findings were
resolved by consensus based on five radiographic features:
cavitary disease, bronchiectasis, nodules, consolidation,
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MATERIALS AND METHODSand tree-in-bud appearance.
14
Treatment protocol 
All patients who began antibiotic therapy received a stan-
dardized combination antibiotic therapy consisting of
clarithromycin (1,000 mg/day), rifampicin (450 mg for
patients who were < 50 kg or 600 mg for patients who
were ≥ 50 kg), and ethambutol (25 mg/kg for 2 months,
then 15 mg/kg/day).
3 These drugs were administered on a
daily basis. Streptomycin was given intramuscularly at 10-
15 mg/kg (500-1,000 mg) three times per week for the first
3-6 months, as far as tolerated in patients with AFB smear-
positive sputum or cavitation on chest radiography. This
regimen usually continued for a total treatment duration of
24 months, including at least 12 months after sputum
culture conversion. Sputum smear and culture examina-
tions were performed monthly for the first six months and
then at two- to three-month intervals until the end of
treatment.
Assessment of microbiologic responses
Sputum conversion was defined as three consecutive
negative cultures within 6 months, with the time of conver-
sion defined as the date of the first negative culture. If
patient could not expectorate sputum during the treatment
duration, the sputum was considered to have converted to
negative. Sputum relapse was defined as two consecutive
positive cultures after sputum conversion.
15,16
For the purpose of these analyses, a favorable microbiol-
ogic response was defined as sputum conversion and
maintenance of negative sputum cultures for more than 12
months. An unfavorable microbiologic response was
defined as follows: 1) no sputum conversion, 2) initial
sputum conversion with sputum relapse, or 3) death related
to MAC lung disease. 
Statistical analysis 
Because a majority of the data did not follow a normal
distribution, all results presented herein are expressed as
the median and interquartile range (IQR) or the number
(percentage) of patients. Categorical variables were
analyzed using the Pearson χ 2-test or Fisher’s exact test.
Continuous variables were analyzed using a Mann-
Whitney U-test. Multiple logistic regression was per-
formed to assess the effects of independent factors on
final treatment outcome (excluding uncertain outcomes).
Variables with a p value less than 0.2 in the univariate
analysis were considered for the multivariate analysis. All
P values were two-sided, with p < 0.05 considered to be
statistically significant. Analyses were executed using
PASW, version 17.0 for Windows (SPSS Inc, Chicago,
IL, USA)
Patient characteristics
A total of 96 patients [40 males and 56 females, median
age 59 years (IQR, 52-68 years)] with MAC lung disease
who had received combination antibiotic therapy were
included in the study. None of the 96 patients showed
positive for HIV. Patient characteristics are summarized in
Table 1. All patients had respiratory symptoms such as
purulent sputum (n = 90; 94%), cough (n = 84; 88%), or
hemoptysis (n = 28; 29%). Etiologic organisms included
M. intracellulare in 56 patients (58%) and M. avium in 40
patients (42%). A total of 66 patients (69%) had a positive
AFB smear at the time of antibiotic therapy initiation.
Cavities (either single or multiple) were visible on chest
radiography in 37 patients (39%). Finally, 61 patients
(64%) had the nodular bronchiectatic form, 25 patients
(26%) had the upper lobe cavitary form, and 10 patients
(10%) had unclassifiable variants.
Drug susceptibility tests were performed as described
previously on MAC isolates recovered from 68 patients,
and none of the MAC isolates showed resistance to clari-
thromycin.
Combination antibiotic treatment 
The median duration of antibiotic therapy was 24 months
(IQR, 18-24 months). Streptomycin was given to 72
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Table 1. The Clinical and Radiographic Characteristics of 96
Patients with Mycobacterium avium Complex Lung Disease
Characteristics
Number or median 
(interquartile range)
Age, yrs 59 (52 - 68)
Gender, female 56 (58%)
Body mass index, kg/m
2 19.9 (18.1 - 22.0)
Non-smoker 72 (75%)
Respiratory symptoms
Cough 84 (88%)
Sputum 90 (94%)
Hemoptysis 28 (29%)
Etiology
Mycobacterium intracellulare 56 (58%)
Mycobacterium avium 40 (42%)
Positive sputum AFB smear 66 (69%)
Type of disease
Nodular bronchiectatic form 61 (64%)
Upper lobe cavitary form 25 (26%)
Unclassifiable form 10 (10%)
AFB, acid-fast bacilli.
RESULTSpatients (75%) for median 4.5 months (IQR, 3-6 months). 
In all, 28 patients (29%) changed treatment regimens
due to side-effects. Of these, 23 (24%) stopped taking
ethambutol due to decreased visual acuity or skin rash after
a median duration of 6 months (IRQ, 3-12 months). A
reduction in the dose of clarithromycin to 500 mg/day was
required in 10 patients due to gastrointestinal disturbance
after a median duration of 1.6 months (IRQ, 0.2-4.2
months). Five patients experienced side-effects associated
with both ethambutol and clarithromycin. 
Surgical resection was performed on eight patients (8%).
The indications for surgery included a lack of sputum
conversion (n = 6) and complications such as recurrent
hemoptysis despite negative sputum conversion (n = 2).
Pulmonary resections included lobectomy in three patients,
segmentectomy in two patients, lobectomy plus segmen-
tectomy in one patient, lobectomy plus wedge resection in
one patient, and pneumonectomy in one patient. Negative
sputum culture conversion was achieved in six patients.
Clinical, radiographic, and microbiologic responses
As shown in Table 2, response rates were 81%, based on
symptoms, and 78% based on HRCT findings. At the start
of treatment, the median ESR was 45.0 mm/hr (IQR, 28.5-
75.0 mm/hr). ESR levels decreased to a median of 14.0
mm/hr (IQR, 7.0-34.0 mm/hr) after 12 months of treat-
ment (p< 0.001). 
Among the 96 patients with MAC lung disease who
received combination antibiotic therapy, the initial sputum
conversion rate was 82% (79/96) and the median time until
sputum conversion was one month (IQR, 1-2 months). Of
the 79 patients who showed initial sputum conversion, 61
patients completed antibiotic treatment and were followed
for a median of 6.5 months (IQR, 3.0-12.3 months). Spu-
tum relapse occurred after treatment completion in three
patients (5, 9, and 16 months after treatment completion,
respectively). Eighteen patients remained on the treatment
for 19.2 months (IQR, 16.1-22.5 months) at the time of
analysis. Therefore, the overall favorable microbiologic
response rate was 79% (76/96). Twenty patients (21%)
had unfavorable microbiologic responses, including failure
to sputum conversion (n = 13), relapse (n = 3), and MAC-
related death (n = 4).
Prognostic factors 
Based on the clinical variables included in the univariate
comparison between favorable and unfavorable micro-
biologic response groups, the final multiple logistic
regression model revealed that a positive sputum AFB
smear at the start of treatment (odds ratio, 9.60; 95%
confidence interval, 1.02-90.19; p = 0.048) was indepen-
dently associated with an unfavorable microbiologic
response (Table 3).
We investigated the efficacy of standardized combination
antibiotic therapy for the treatment of patients with MAC
lung disease. Treatment included oral clarithromycin,
rifampicin, and ethambutol in combination with the aggres-
sive use of intramuscular streptomycin during the initial
treatment period. The overall favorable microbiologic
response rate was 79% (76/96), and we found that a posi-
tive sputum AFB smear at the start of treatment was ind-
ependently associated with an unfavorable microbiologic
response.
The optimal treatment regimen for MAC lung disease
has yet to be fully established.
4,17 Field, et al.
5 published a
comprehensive literature review of potential treatments for
MAC lung disease. Overall, treatment outcomes have
improved with the addition of macrolides to the standard
regimen; however, the average culture conversion rate
from 12 studies using the macrolide-containing regimen
was only about 60%.
5 In our study, the favorable micro-
biologic response rate was 79%. This relatively high treat-
ment response rate is comparable to data from previous
studies in Japan.
18,19 In these Japanese studies, all patients
received clarithromycin, rifampicin, and ethambutol daily,
and 65-70% of patients were treated with an aminogly-
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DISCUSSION
Table 2.Treatment Responses of 96 Patients with Mycobac-
terium avium Complex Lung Disease
Treatment responses No. (%) of patients
Symptomatic responses (n = 95)*
Improved 77 (81)
Unchanged 8 (8)
Worsened 10 (11)
Radiographic responses on HRCT (n = 87)
�
Improved 68  (78)
Unchanged 10 (12)
Worsened 9 (10)
Microbiologic responses (n = 96)
Initial sputum conversion and  76 (79)
maintenance of conversion
Initial sputum conversion,  3 (3)
with sputum relapse
Failure to sputum conversion 17 (18 )
HRCT, high-resolution computed tomography.
*Outpatient medical record was not available in one patient.
�Follow-up HRCT scans were available in 87 patients and were performed at
a median 11.9 months (interquartile range, 11.6 - 12.3 months) after the start
of antibiotic therapy.coside such as streptomycin or kanamycin for the initial 2-
6 months of therapy. In these studies, long-term conver-
sion rates were more than 80% in patients infected with
clarithromycin-susceptible strains.
18,19
The role of aminoglycoside as a companion drug is
somewhat unclear. Streptomycin may be useful in patients
who have a substantial number of extracellular organisms
against which streptomycin is highly active. Included in
this group are patients with radiographically extensive or
cavitary disease and those with strongly positive sputum
AFB smears. A recent prospective randomized controlled
study of the clinical efficacy of streptomycin in the treat-
ment of MAC lung disease revealed that sputum conver-
sion rates at the completion of therapy were significantly
higher in the streptomycin group who received streptomy-
cin intramuscularly three times per week for the initial 3
months of therapy in combination with clarithromycin,
rifampicin, and ethambutol.
16 In our study, streptomycin
was given for a median of 4.5 months (IQR, 3-6 months)
in 72 patients (75%). The use of this aggressive treatment
strategy depended largely on the patients’ characteristics.
We used streptomycin in patients with a positive sputum
smear and/or cavitary disease. Among the 96 patients, 66
(69%) had a positive AFB smear and 37 (39%) had a cavity
(or cavities) visible on chest radiography at the start of
antibiotic therapy. 
Some small-scale studies suggest that a three-times-
weekly regimen that includes clarithromycin or azithromy-
cin may be as effective as a daily regimen.
20,21 However, a
large prospective trial showed that a three-times-weekly
regimen was not effective in producing negative culture
conversion.
14 Negative culture conversion was achieved in
only 13% of patients (4% in the cavitary disease group and
24% in the non-cavitary disease group), although culture
improvement rates, i.e., reduction in colony counts, were
44% (20% in the cavitary disease group and 71% in the
non-cavitary disease group).
14 The Korean Academy of
Tuberculosis and Respiratory Diseases recommends a
daily antibiotic therapy for MAC lung disease.
6 Therefore,
all patients in our study who required antibiotic therapy
were given a daily regimen according to the national
guidelines.
With respect to treatment duration, it is usually recom-
mended that antibiotic therapy be continued for 12 months
once the patient converts to a negative culture.
3,4 The over-
all treatment period in our study was typically 24 months.
In some studies, however, high relapse rates have been
reported despite long-term antibiotic therapy of ≥ 24
months.
22 Genotyping research has demonstrated that in
patients with nodular bronchiectatic forms of MAC lung
disease, multiple and/or repeated infections and frequent
recurrence may be due to reinfection with a genetically
different strain or relapse with the original strain.
23,24 Recent
studies have provided evidence that a patient’s home envi-
ronment, e.g., bathrooms, may serve as a continuing source
of pulmonary infection caused by MAC.
25,26 When patients
repeatedly inhale MAC organisms during treatment, the
efficacy of antibiotic therapy may be reduced. Future
studies examining the clinical relevance of these situations
should be performed.
As the American Thoracic Society guidelines pointed
out, one of the most difficult questions may be when to
Yun Su Sim, et al.
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Table 3.Predictors of Favorable Microbiologic Responses in Patients with Certain Outcomes (n = 96)
Favorable   Unfavorable Univariate
Multivariate logistic regression
Patient characteristic response  response analysis
(n = 76) (n = 20) pvalue pvalue OR (95% CI)
Age > 50 yrs 59 (78%) 17 (85%) 0.470 0.662 1.43 (0.29 - 7.07)
Gender, female 50 (66%) 6 (30%) 0.004 0.065 0.24 (0.06 - 1.16)
Body mass index < 18.5 kg/m
2 19 (25%) 8 (40%) 0.184 0.253 2.09 (0.59 - 7.37)
Comorbidity 17 (22%) 7 (35%) 0.246 - -
Current or former smoker 15 (20%) 9 (45%) 0.020 0.426 1.92 (0.38 - 9.65)
Mycobacterium intracellulare 41 (54%) 15 (75%) 0.089 0.113 2.76 (0.79 - 9.66)
Upper lobe cavitary form  18 (24%) 8 (40%) 0.144 0.410 1.80 (0.45 - 7.23)
Nodular bronchiectatic form 51 (84%) 10 (17%) 0.157 - -
No. of involved lobes on HRCT ≥5* 24 (32%) 5 (25%) 0.569 - -
Positive sputum AFB smear  49 (65%) 19 (95%) 0.008 0.048 9.60 (1.02 - 90.19)
Combined use of streptomycin 55 (72%) 17 (85%) 0.246 - -
Stopped use of ethambutol 18 (24%) 5 (25%) 1.000 - -
Dose reduction of clarithromycin 8 (11%) 2 (10%) 0.945 - -
IQR, interquartile range; OR, odds ratio; CI, confidence interval; AFB, acid-fast bacill; HRCT, high-resolution computed tomography.
*A total of six lobes in each patient’s lung (the lingular segment was considered as a separate lobe) were assessed.start antibiotic therapy in patients with MAC lung disease.
3,4
The decision to begin treatment is made by weighing the
anticipated benefits and risks. The decision is relatively
easy in patients with profound symptoms and destructive
lesions; however, the decision is difficult in patients with
mild symptoms and non-advanced lesions. Factors that
must be considered include the patients’ age, whether the
symptoms are mild or equivocal, and the presence of
comorbities.
27 In all cases, close observation is necessary if
treatment is not performed. 
There are few studies in which patients with certain
characteristics show disease progression. One study from
Japan found that 60% of patients showed disease progres-
sion and 40% of patients were stable during a mean
observation period of 28 months.
28 In the present study, the
conversion rate was significantly higher in smear-negative
cases, suggesting that the earlier the treatment starts, the
better the outcomes will be. However, prolonged antibiotic
treatment may not be necessary in patients in the early
stages of infection. This is a real challenge to clinicians in
daily practice. Further studies are needed to determine
when to start antibiotic therapy.
The present study has many limitations that are inherent
to all retrospective, noncomparative studies conducted at a
single center. We did not calculate appropriate power or
sample size for this study at the design stage. Our restros-
pective study may have less power (less than 80%) to
detect predictors of favorable responses if the expected
proportion of favorable response was 0.2, and 95% of the
patients with the favorable category of a predictor to favo-
rable response resulted in favorable response, and the
candidate predictors are not correlated. As observed therapy
was not performed directly for patients with NTM lung
disease, the possibility of poor compliance of treatment
regimen could not be completely excluded in this retros-
pective study. In addition, the present study included pat-
ients with newly diagnosed MAC lung disease, and no
patients were infected with clarithromycin-resistant MAC
isolates. Therefore, our high treatment response rates may
not be generalized to patients with a previous treatment
history or those infected with clarithromycin-resistant
isolates. Most importantly, we cannot determine whether a
favorable microbiologic response will continue. Of the 76
patients who achieved culture-negative sputum for more
than 12 months, 61 completed their antibiotic therapy and
underwent follow-up for a median of only 6.5 months.
Longer follow-up times are necessary to fully assess
disease relapse over time.
In conclusion, standardized combination antibiotic
therapy consisting of clarithromycin, rifampicin, and
ethambutol with or without initial use of streptomycin is
effective in treating patients with newly diagnosed MAC
lung disease. Further studies are needed to address several
issues regarding optimal timing of antibiotic therapy,
treatment regimens, and treatment duration.
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